Company intelligence / Profile preview

SOLX

Waltham, Massachusetts, United Statessolx.ph ↗

Ownership: Private
Development stage: Commercial

Overview

SOLX developed ophthalmic devices for glaucoma management, including the SOLX Gold Shunt implant and the SOLX 790 Laser. The Gold Shunt received Health Canada clearance and CE approval in Europe. Clinical data showed a significant reduction (~45.6%) in intraocular pressure at one year post-surgery for patients with refractory glaucoma. Both products were also involved in randomized, multi-center studies in the US

Therapeutic areas: Ophthalmology
Modalities: DeviceImplantable deviceLaser-based therapy
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on SOLX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOLX.

Explore the full profile